Tonix Pharmaceuticals (NASDAQ:TNXP) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report issued to clients and investors on Friday. The firm set a “sell” rating on the stock.

Separately, Dawson James started coverage on Tonix Pharmaceuticals in a research report on Wednesday, February 28th. They set a “buy” rating and a $3.00 target price for the company.

Tonix Pharmaceuticals Price Performance

Shares of Tonix Pharmaceuticals stock opened at $0.16 on Friday. The stock has a market cap of $13.26 million, a price-to-earnings ratio of -0.02 and a beta of 2.21. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.81 and a current ratio of 2.53. The stock has a 50 day moving average price of $0.30 and a 200-day moving average price of $0.39. Tonix Pharmaceuticals has a one year low of $0.12 and a one year high of $3.31.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Monday, April 1st. The company reported ($0.86) EPS for the quarter. The business had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.95 million. Equities analysts expect that Tonix Pharmaceuticals will post -3.71 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in Tonix Pharmaceuticals by 12.3% in the 1st quarter. BlackRock Inc. now owns 34,392,362 shares of the company’s stock worth $7,916,000 after acquiring an additional 3,760,804 shares in the last quarter. Renaissance Technologies LLC raised its position in Tonix Pharmaceuticals by 79.4% during the 1st quarter. Renaissance Technologies LLC now owns 19,200,435 shares of the company’s stock valued at $4,420,000 after purchasing an additional 8,500,604 shares in the last quarter. State Street Corp lifted its holdings in shares of Tonix Pharmaceuticals by 11.4% in the 1st quarter. State Street Corp now owns 7,446,104 shares of the company’s stock worth $1,714,000 after buying an additional 764,518 shares during the period. Northern Trust Corp grew its position in shares of Tonix Pharmaceuticals by 7.8% during the 1st quarter. Northern Trust Corp now owns 4,139,924 shares of the company’s stock worth $952,000 after buying an additional 300,199 shares in the last quarter. Finally, Armistice Capital LLC increased its stake in shares of Tonix Pharmaceuticals by 160.0% during the fourth quarter. Armistice Capital LLC now owns 3,770,000 shares of the company’s stock valued at $1,519,000 after buying an additional 2,320,000 shares during the period. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.